SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
ULBI 10.94-1.9%Jul 19 4:30 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (3288)3/20/2013 8:44:44 AM
From: richardred2 Recommendations  Read Replies (2) of 7071
 
Bulls-eye -today in OMPI- first successful takeout pick this year.:+ )

Valeant to buy Obagi Medical for about $344 mln

Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio.

The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price.

Obagi's board has unanimously approved the deal, Valeant said in a statement.
reuters.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext